INTRODUCTION

For absorption of oral formulations, solubility and permeability are act as two major factors. Nowadays, some of the new chemical entities are poor water solubility drugs. Therefore, improving the drug bioavailability is the most tough challenge of solid oral dosage formulations. Solid dispersion is one of the most successful technologies to enhance the solubility of drug. In this approach, drug is converted to enhance the solubility and dissolution of drug. In this approach, drug is converted form to an amorphous structure form. The results show that the formulation of Ibacaftor SDs by HMT has become more solubility and bioavailability [1-3].

The process of hot melt extrusion (HME) is one of the solid dispersion (SD) technique that efficient mixing of drug with polymer and inert excipient, progressive melting and finally solidified. The drug-polymer ratio, quantity of surfactant, selection of polymer, extrusion temperature, and screw rotation speed are important parameters; it can affect quality and solubility of drug product. For example, the screw rotation speed may impact the proper conversion of polymorphic form and mixing of polymer and surfactant [4,5].

Fig 1, represents Chemical structure of Ivacaftor is a cystic fibrosis transmembrane conductance regulator potentiator indicated for the treatment of cystic fibrosis. Ivacaftor is a white to off-white crystalline powder. The crystalline form of the drug substances is practically insoluble in aqueous media (<0.001 mg/mL). To increase the solubility of Ivacaftor, HME technology was selected. Therefore, the selection of polymer carrier able to conversion of polymorphic form of Ivacaftor, along with effects keeping Ivacaftor in amorphous state [6,7].

The present study was carried out to develop Ivacaftor SD by HME (Fig. 2). Technology using three different polymers and three different surfactants of enhancing drug solubility. By different prototype formulations select one optimize formulation based on dissolution profile and perform factorial design.

MATERIALS AND METHODS

Materials

Ivacaftor drug substance was gift sample of Aurobindo pharma Ltd., Hyderabad, India. Cellulose microcrystalline (Avicel pH 102) was gifted by FMC Biopolymer, USA. Hypromellose 5 cps was gift sample of Dow Chemical, USA. Aerosil 200 (colloidal silicon dioxide) was gifted by Evonik, Germany. Polysorbate 80 was gift sample of BASF, and poloxamer were gift sample of BASF, and poloxamer 80 was gifted by Seppic. Croscarmellose sodium was gifted by DFE Pharma, Germany, and magnesium stearate was given by Peter Green, the Netherlands.

HME

Preparation of Ivacaftor SDs by HME

Ivacaftor SD was prepared by different carriers such as Copovidone, Soluplus, and Hypromellose 5 cps along with surfactants such as sodium lauryl sulfate, poloxamer, and polysorbate 80. HME Pharma 24 - Thermo Fisher twin screw model was used for the preparation of SDs using feed rate of 1–1.3 Kg/h, torque: 4 Barr, and 10 different temperature zones from 20°C–2°C to 210°C–2°C with chillers zone maintain at temperature 2–5°C (where melt was converted into flake pieces).

Manufacturing process

- Step 1: Ivacaftor was taken with Copovidone (one set of trials), Hypromellose 5 cps (second set of trials), and Soluplus (third set of trials) along with surfactants such as sodium lauryl sulfate, poloxamer.
and polysorbate 80 which were sifted through #40 mesh and mixed well using poly bag for 10 min. Polysorbate 80 is available in liquid state so dilute with water as 10% solids and coating into plain Ivacaftor API by using FBP. The above material was hot-melt extruded using above mentioned at different temperature zones (Table 1). Table 2, represents composition of Ivacaftor by HME. The extrudes were transparent in FHM2, FHM3, FHM5, FHM6, FHM8, and FHM9. Remaining extrudes were opaque in nature. The extrudes crushed into mortar and pestle. The powder was granular in nature and sifted through #30 mesh.

- **Step 2:** The extrudes of step no 1, cellulose microcrystalline (Avicel pH 102), croscarmellose sodium (Ac-Di-Sol), and colloidal silicon dioxide (Aerosil 200) were sifted through #30 mesh and mixed well using poly bag for 10 min.
- **Step 3:** Magnesium stearate sifted through #40 mesh and added to step no 2 mixed in poly bag for 5 min manually.

![Fig. 1: Chemical structure of Ivacaftor](image)

**Table 1: Temperatures to be monitored during HME process**

| Name of zones       | Temperature         |
|---------------------|---------------------|
| Barrel conveying    | 20°C±2°C             |
| Zone H              | 20°C±2°C             |
| Zone III            | 80°C±2°C             |
| Zone IV             | 120°C±2°C            |
| Zone V              | 180°C±2°C            |
| Zone VI             | 210°C±2°C            |
| Zone VII            | 210°C±2°C            |
| Zone VIII           | 210°C±2°C            |
| Zone IX             | 80°C±2°C             |
| Zone X              | 50°C±2°C             |
| Die zone            | 20°C±2°C             |
| Chillers/cooling    | Maintained at temperature 2-5°C (where melt was converted into pieces of flakes) |

**Table 2: Composition of Ivacaftor SDs by HME**

| S. No | Ingredients (Units) | FHM1 | FHM2 | FHM3 | FHM4 | FHM5 | FHM6 | FHM7 | FHM8 | FHM9 |
|-------|---------------------|------|------|------|------|------|------|------|------|------|
| 1.    | Ivacaftor (mg)      | 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0|
| 2.    | Copovidone (mg)     | 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0| 150.0|
| 3.    | Hypromellose 5 cps (mg) | -    | -    | -    | 150.0| 150.0| 150.0| 150.0| -    | -    |
| 4.    | Soluplus (mg)       | -    | -    | -    | -    | -    | 150.0| 150.0| 150.0| 150.0|
| 5.    | Sodium lauryl sulfate (mg) | 15.0 | -    | -    | -    | -    | -    | 15.0 | -    | -    |
| 6.    | Poloxamer (mg)      | -    | 15.0 | -    | 15.0 | -    | 15.0 | -    | 15.0 | -    |
| 7.    | Polysorbate 80 (mg) | -    | -    | -    | 15.0 | -    | 15.0 | -    | 15.0 | -    |
| 8.    | Total quantity of HME material weight (mg) | 315.0 | 315.0 | 315.0 | 315.0 | 315.0 | 315.0 | 315.0 | 315.0 | 315.0 |
| 9.    | Microcrystalline cellulose (Avicel pH 102) (mg) | 214.5 | 214.5 | 214.5 | 214.5 | 214.5 | 214.5 | 214.5 | 214.5 | 214.5 |
| 10.   | Croscarmellose sodium (Ac-Di-Sol) (mg) | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 |
| 11.   | Colloidal silicon dioxide (Aerosil 200) (mg) | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 |

**Evaluation of Ivacaftor SDs**

**Solubility studies of Ivacaftor SDs**

Solubility measurements of Ivacaftor were performed with solvent shaken for the 12 h at room temperature. Subsequently, the suspensions were filtered through a Whatman filter paper. A filtered solution of Ivacaftor was analyzed using UV 255 nm.

**Drug content**

Solid dispersions equivalent to 150 mg of Ivacaftor were weighed accurately and dissolved in 100 ml of 0.1% trifluoroacetic acid: acetonitrile (20:80 ratio). The solution was filtered and diluted with the suitable amount, and drug content was analyzed at λ 255 nm against blank using UV spectrometer [8]. The actual drug content was calculated using the following equation:

\[
\% \text{Drug content} = \frac{\text{Actual amount of drug in solid dispersion}}{\text{Theoretical amount of drug in solid dispersion}} \times 100
\]

**In vitro drug release studies**

The in vitro drug release profile for each SD as well as plain drug was performed using USP type 2 dissolution apparatus. The sample equivalent to 150 mg of Ivacaftor was added and the conditions maintained are shown in Table 3.

The samples were drawn at specified time intervals, and the obtained samples were analyzed using UV-visible spectrophotometer at 255 nm. The cumulative percentage release was calculated [9].

**RESULTS AND DISCUSSION**

**Fourier-transform infrared (FT-IR) spectrometry studies**

FT-IR spectrum majorly was used to determine if any of interaction between the drug and excipient used. The prominent peaks of Ivacaftor were observed (Fig. 3) the region: 332 cm\(^{-1}\) due to >N-H (N-H stretching), 2957 cm\(^{-1}\) due to –O-H (-OH stretching), and 1647 cm\(^{-1}\) due to –C=O (stretch). The optimized formulation FSD8 (Fig. 4) displayed the characteristic peaks at wave numbers nearer to that of plain Ivacaftor (Fig. 3). Overall, there was no alteration in the characteristic peaks of the optimized formulation, suggesting that there was no interaction between the drug and polymers.

**Differential scanning calorimetry (DSC)**

The DSC thermogram of plain Ivacaftor is shown in Fig. 5, sharp peak of endothermic at 205°C melting point, indicating that the drug was crystalline. The absence of peaks in the SD of formulation FHM9 (Ivacaftor: Soluplus (1:1) with poloxamer) indicates that the drug was converted in amorphous form [10].

---

**Table 3: Ingredients and properties of the optimized formulation FSD8**

| S. No | Name of zones       | Temperature         |
|-------|---------------------|---------------------|
| 1.    | Barrel conveying    | 20°C±2°C             |
| 2.    | Zone H              | 20°C±2°C             |
| 3.    | Zone III            | 80°C±2°C             |
| 4.    | Zone IV             | 120°C±2°C            |
| 5.    | Zone V              | 180°C±2°C            |
| 6.    | Zone VI             | 210°C±2°C            |
| 7.    | Zone VII            | 210°C±2°C            |
| 8.    | Zone VIII           | 210°C±2°C            |
| 9.    | Zone IX             | 80°C±2°C             |
| 10.   | Zone X              | 50°C±2°C             |
| 11.   | Die zone            | 20°C±2°C             |
| 12.   | Chiller/cooling     | Maintained at temperature 2-5°C (where melt was converted into pieces of flakes) |

**HME: Hot-melt extrusion, SD: Solid dispersions**
X-ray diffraction (XRD) analysis
The XRD of Ivacaftor observed that multiple sharp peaks (Fig. 6) indicates that the drug was in crystalline nature. SD optimized formulation FHM8 (Ivacaftor: Soluplus (1:1) with poloxamer) when exposed to X-ray beam observed no crystalline endothermic peaks and characteristic intensities of Ivacaftor (Fig. 7). This indicates that complete conversion of crystalline Ivacaftor into amorphous polymorphic state during hot melt extrusion process. From the XRD studies, it is clearly confirmed that HME of batch no FHM8 drug substance converted into amorphous form [11].

Scanning electron microscopy (SEM)
HMEs of FHM8 performed surface micrographs, and plain Ivacaftor was determined into SEM technique. The SEM micrograph of plain Ivacaftor
Nine formulations of the SDs were prepared using HME technique with respective polymer. After preparation of SDs using HME process, the resulting extruded mixture was analyzed for solubility of drug and was compared with plain drug itself (Table 4). The formulation of (Ivacaftor: soluplus (1:1) with poloxamer) FHM8 represents the solubility enhancement as compared to plain drug (plain drug solubility is 0.001 mg/ml) [14,15].

In vitro dissolution studies

The obtained drug release data for formulations FHM1 to FHM9 are shown in Fig 9. Table 6 shows the cumulative percentage drug released for all formulations. Cumulative percentage of drug released after 30 min was 72%, 77%, 78%, 80%, 85%, 82%, 89%, 95%, and 93% for FHM1–FHM9, respectively, and was 9% in 30 min for plain drug. In vitro studies reveal that there is a marked increase in the dissolution rate of Ivacaftor from all the SDs when compared to plain drug itself. From the in vitro drug release profiles, formulation FHM8 containing Ivacaftor: Soluplus (1:1) with surfactant poloxamer was best formulation which shows high dissolution rate, i.e., 95.0% compared with other formulations. This may attributed to increase the conversion of drug to amorphous (Table 5).

The dissolution profiles of Ivacaftor SDs prepared by HME (FHM8) shown that the % drug release was more compared with all nine formulations. The SD formulations by FHM8 shown highest drug release, i.e., 95.0%, respectively, after 30 min, where plain drug release was only 9%.

Evaluation parameters

Solubility studies of Ivacaftor SDs

Nine formulations of the SDs were prepared using HME technique with respective polymer. After preparation of SDs using HME process, the resulting extruded mixture was analyzed for solubility of drug and was compared with plain drug itself (Table 4). The formulation of (Ivacaftor: soluplus (1:1) with poloxamer) FHM8 represents the solubility enhancement as compared to plain drug (plain drug solubility is 0.001 mg/ml) [14,15].

Table 4: Solubility in aqueous media and drug content of SDs prepared by HME method

| S. No. | Formulation | Solubility (mg/ml) | % Drug content |
|--------|-------------|--------------------|---------------|
| 1      | Plain drug  | 0.001              | -             |
| 2      | FHM8        | 0.25               | 98.5%         |

HME: Hot-melt extrusion, SD: Solid dispersions

(Fig. 8) was observed crystalline drug agglomerates with ordered shape and size (Fig. 8). The surface characteristics extrude of optimized formulation FHM8 [12,13].

In vitro dissolution studies

The obtained drug release data for formulations FHM1 to FHM9 are shown in Fig 9. Table 6 shows the cumulative percentage drug released for all formulations. Cumulative percentage of drug released after 30 min was 72%, 77%, 78%, 80%, 85%, 82%, 89%, 95%, and 93% for FHM1–FHM9, respectively, and was 9% in 30 min for plain drug. In vitro studies reveal that there is a marked increase in the dissolution rate of Ivacaftor from all the SDs when compared to plain drug itself. From the in vitro drug release profiles, formulation FHM8 containing Ivacaftor: Soluplus (1:1) with surfactant poloxamer was best formulation which shows high dissolution rate, i.e., 95.0% compared with other formulations. This may attributed to increase the conversion of drug to amorphous (Table 5).

The dissolution profiles of Ivacaftor SDs prepared by HME (FHM8) shown that the % drug release was more compared with all nine formulations. The SD formulations by FHM8 shown highest drug release, i.e., 95.0%, respectively, after 30 min, where plain drug release was only 9%.

Statistical analysis

Based on the preliminary feasibility study, a design of experiments (DOE) with full factorial design (Table 7) was performed to optimize Soluplus and poloxamer concentrations used in the formulation. Percentage of drug release in 30 min was identified as a critical parameter.
The dissolution profile of the formulations was evaluated using USP apparatus II (Paddle) at 65 rpm in pH 6.8 sodium phosphate buffer with 0.7% sodium dodecyl sulfate, 900 mL. The drug release at 30 min was also evaluated.

A constant tablet weight of 550.00 mg was used by compensating the quantity with the diluent (Microcrystalline cellulose [Avicel pH 102]) to achieve the target weight. The goal of formulation development was to select the optimize Soluplus and poloxamer concentrations and to understand if there was any interaction within the variables. This study also sought to establish the robustness of the proposed formulation.

Initially, $2^2$ full factorial DOE with one center points was studied, and from the results of the formulation trails using Design-Expert® 11 Software, the table no 8 , summarizes the factors as soluplus, poloxamer and responses as dissolution in 30 min studied for subjected to dissolution testing.

The experimental results for dissolution ($Y_1$) are presented in Table 8.

A constant tablet weight of 550.00 mg was used by compensating the quantity with the diluent [Microcrystalline cellulose [Avicel pH 102]] to achieve the target weight. The goal of formulation development was to select the optimize Soluplus and poloxamer concentrations and to understand if there was any interaction within the variables. This study also sought to establish the robustness of the proposed formulation. Initially, $2^2$ full factorial DOE with one center points was studied, and from the results of the formulation trails using Design-Expert® 11 Software, the table no 8 , summarizes the factors as soluplus, poloxamer and responses as dissolution in 30 min studied for subjected to dissolution testing.

The experimental results for dissolution ($Y_1$) are presented in Table 8.

Fig 10, represents the % drug release of optimum batch (FHM8) and DOE trial batches. Using different concentrations of Soluplus shows major effect of dissolution profile. By using soluplus concentration 75 mg shows the significant effect on dissolution profile and using 150 mg, 225 mg represents no significant effect on dissolution. There is
no significant effect by using poloxamer at different concentrations on dissolution was observed. Poloxamer used in different concentrations from 7.5 to 22.5 shows no significant effect of formulation. So there is no much effect on dissolution by using poloxamer. (Table 9)

A two-factor experimental design represents p-value that shows a significant effect of the formulation. p<0.05 shows a significant effect and p>0.05 represents the non-significant effect. Data given in Table 10 demonstrate that p=0.0103 which is <0.05 the selected model shows a
significant effect. For Soluplus, \( p=0.00656 \) shows the significant effect by changing the concentration of Soluplus. For poloxamer \( p=0.126 \) which represents not significant effect by using different poloxamer concentrations.

From the above half normal plot, the formulation variables on dissolution in 30 min show a significant effect by using different concentrations of soluplus and poloxamer (Fig 12). Soluplus shows the longest effect in half-normal plot and Pareto chart (Fig 11). Dissolution time in the formulation of the range studied is within the proposed specification limit (NLT 80\% drug release in 30 min). Hence, in the present formulation, 150.0 mg per tablet of Soluplus and 15 mg poloxamer per tablet were selected for the finalized formulation.

Two-dimensional contour plots and three-dimensional response surface plots for variables are shown in Figs 13 and 14, respectively.

### Table 9: Dissolution profiles of the formulations

| Time (min) | FHM8 | FHM10 | FHM11 | FHM12 | FHM13 |
|------------|------|-------|-------|-------|-------|
| Dissolution profile | | | | | |
| 5          | 45   | 48    | 47    | 19    | 18    |
| 10         | 72   | 75    | 72    | 37    | 35    |
| 15         | 92   | 93    | 91    | 42    | 42    |
| 20         | 94   | 94    | 93    | 45    | 45    |
| 30         | 95   | 96    | 94    | 47    | 45    |

Fig. 13: Contour model plot

Fig. 14: Three-dimensional response surface plots
They were used to study the interaction effects of the independent factors on the responses at 1 time. The contour plot is formed by vertical axis and horizontal axis. The horizontal axis represents Soluplus and the vertical axis represents poloxamer.

CONCLUSION
In the present study, the SDs of the poorly soluble drug substance Ivacaftor were successfully prepared using HME. The in vitro dissolution test shows a significant increase in dissolution rate of SDs prepared by HME (95%) in formulation FHM8 compared with plain Ivacaftor (9%) within 30 min. The release of drug was slightly on the higher side at initial time point from Ivacaftor SD technique by hot-melt extrusion technique. The increase in dissolution rate of Ivacaftor is in order of SDs of HME > plain drug substance. DOE results show the significant effect using Soluplus. The mechanism involved in solubilization by improved wetting of drug substance by hydrophilic carriers represents rich with microenvironment formed at the surface of the drug substance which leads to improves dissolution rate. The crystallinity nature of drug substance was reduced in SD technique by formulation with polymers. The results from FT-IR concluded that there was no defined interaction between Ivacaftor and carriers. DSC and XRD results showed a conversion of crystal structure toward to amorphous form of Ivacaftor. Finally concluded that HMT of Ivacaftor by using hydrophilic polymers would improved the aqueous dissolution rate, solubility and thereby enhance its systemic availability.

AUTHORS’ CONTRIBUTIONS
The authors would like to thank Dr. Srinivas Lankalapalli for helping review, final corrections, and approved the final version of the manuscript.

CONFLICTS OF INTEREST
The authors declared that they have no conflicts of interest.

REFERENCES
1. Aitken-Nichol C, Zhang F, McGinity JW. Hot melt extrusion of acrylic films. Pharm Res 1996;13:804-8.
2. Smita D, Sontakke SB. Solubility enhancement of gliclazide by solid dispersion method. Asian J Pharm Clin Res 2013;6 suppl 5:91-8.
3. Nidhalhakazza M, Anastarik A, Ameerabab E. Efficacy of combination solid dispersion technology on dissolution performance of naldixic acid and cefditrin. Asian J Pharm Clin Res 2017;7:394-401.
4. Agrawal AM, Dudhedia MS, Zimmey E. Hot melt extrusion: Development of an amorphous solid dispersion for an insoluble drug from mini-scale to clinical scale. AAPS Pharm Sci Tech 2016;17:133-47.
5. Wagh K, Crowley MS, Schroeder BC, Fredersdorf AS, Obara SH, Talarico MG. Design and evaluation of bilayer tablets of glimepiride and metformin hydrochloride with combination of hydrophilic and hydrophobic polymers by hot melt extrusion. Asian J Pharm Clin Res 2014;7:300-4.
6. Guns S, Dereymaker A, Kayaert P, Mathot V, Martens JA, Van den Mooter G, et al. Preparation and characterization of celecoxib dispersions in soluplus®: Comparison of spray drying and conventional methods. Iran J Pharm Res 2015;14:35-50.
7. Huang S, O’Donnell KP, Delpon de Vaux SM, O’Brien J, Stutzman J, Williams RO 3rd, et al. Processing thermally labile drugs by hot-melt extrusion: The lesson with glisamide. Eur J Pharm Biopharm 2017;119:56-67.
8. Huq S, Garekani H. Preparation and characterization of celecoxib dispersions in soluplus(®): Comparison of spray drying and conventional methods. AAPS Pharm Sci Tech 2020;21:756-762.
9. Metha S, Joseph NM, Feleke F, Palani S. Improving solubility of BCS class II drugs using solid dispersion. J Drug Deliv Ther 2014;4:7-13.
10. Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 2013;26:768-72.
11. Mohanty S, Jinno J, Kamada N, Miyake M, Yamada K, Makai T. Dissolution enhancement of Seroquel by solid dispersion techniques. Asian J Pharm Clin Res 2010;11:284-7.

Table 10: ANOVA for selected factorial model, response 1: Dissolution

| Source     | Sum of squares | df  | Mean square | F-value | p-value | Significant |
|------------|----------------|-----|-------------|---------|---------|-------------|
| Model      | 2.36E+03       | 2   | 1.18E+03    | 4.72E+03| 0.0103  |             |
| A-Soluplus | 2.35E+03       | 1   | 2.35E+03    | 9.41E+03| 0.0065  |             |
| B-poloxamer| 6.25           | 1   | 6.25        | 2.35E+03| 0.126   |             |
| Curvature  | 470.0          | 1   | 470.0       | 1.88E+03| 0.0147  |             |
| Residual   | 0.250          |     | 0.250       | 0.250   |         |             |
| Cor total  | 2.83E+03       | 4   |             |         |         |             |

Guntaka and Lankalapalli
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 356-363